NEW YORK (Thomson Financial) - Abiomed Inc. Wednesday received approval from
the Food and Drug Administration for U.S. commercial distribution of its iPulse
circulatory support system.
The iPulse, which drives Abiomed's and other manufacturer's intra-aortic
balloons (IAB) and ventricular assist devices (VAD), is the first console with
the capability to provide either VAD or IAB support in the catheterization lab
and surgery suite, according to Abiomed.
"This is an important milestone for Abiomed and an opportune time to be
entering the $200 million IAB market," the company said.
Shares of the Danvers, Mass.-based company, which develops medical products
for failing hearts, closed Tuesday at $14.71.
Melinda Peer
mp/pc
COPYRIGHT
Copyright Thomson Financial News Limited 2007. All rights reserved.
The copying, republication or redistribution of Thomson Financial News Content,
including by framing or similar means, is expressly prohibited without the prior
written consent of Thomson Financial News.
|